Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01692223 · ClinicalTrials.gov registry record
A Safety Study Assessing the Effects of Receiving Genome Sequencing Results
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 8
- Enrollment target
NCT01692223: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01692223 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01692223 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
This study uses new methods called "genome sequencing" that allow the investigators to study part or all of a person's genome. The genome is the collection of all of a person's genes. Genes carry the instructions that our bodies need to develop and function. Genes are passed on from one generation to the next. Genome sequencing can study all of a person's genome (whole genome sequencing) or just parts of their genome (whole exome sequencing). In the study, the investigators refer to all these research methods as 'genome sequencing'. Genome sequencing typically shows a large number of gene changes, known as "variants." Some (but not all) of these genetic variants may be linked to increased risks of diseases other than cancer. The purpose of this study is to learn what kinds of genetic variants the patient wants to learn about from their genome.
Interventions
- BEHAVIORAL qualitative interviews
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-09 |
| Est. Completion | 2018-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01692223
The ClinicalTrials.gov registry entry for NCT01692223 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which qualitative interviews is the first listed.
NCT01692223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01692223 about?
NCT01692223 is a clinical study titled "A Safety Study Assessing the Effects of Receiving Genome Sequencing Results". This study uses new methods called "genome sequencing" that allow the investigators to study part or all of a person's genome. The genome is the collection of all of a person's genes. Genes carry the instructions that our bodies need to develop and function. Genes are passed on from one generation t...
What is the current status of trial NCT01692223?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2012-09. Estimated completion is 2018-08.
What interventions are being tested in trial NCT01692223?
The interventions under investigation include: qualitative interviews (BEHAVIORAL).
Who is sponsoring clinical trial NCT01692223?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.